monoclonal antibodies

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

By MedXY 01/06/2026

A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial hemorrhage risks.

Cardiology news

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results

By MedXY 12/25/2025

A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the results suggest a breakthrough in active amyloid clearance.

Infectious Diseases Internal Medicine news

Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads

By MedXY 12/23/2025

The RECOVERY trial demonstrates that sotrovimab significantly reduces 28-day mortality in hospitalized COVID-19 patients with high baseline serum antigen levels, highlighting the potential for biomarker-guided monoclonal antibody therapy despite the challenges of evolving viral variants.

Clinical Updates HIV/AIDS news

Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS

By MedXY 11/13/2025

This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention and therapy.

Gastroenterology news

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY 10/28/2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising therapeutic target for PSC.

Neurology news Public Health

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies

By MedXY 10/10/2025

Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventive approaches herald a new era in personalized dementia care.

Allergy & Immunology Clinical Updates Nephrology Specialties

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

By MedXY 08/24/2025

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-modifying therapeutic options.